Functional analysis suggests that downregulation of CD33 may be beneficial to AD since amyloid levels were reduced in a mouse model of AD (APPswe/PS1dE9) that were also CD33−/− [73,74]. This evidence concerns the gene CD33 and Alzheimer disease.